Do congenital bleeding disorders have a protective effect against COVID‐19? A prospective study

Dorgalaleh, Akbar; Tabibian, Shadi; Mohammadamini, Mahboobeh; Bahraini, Mehran; Dabbagh, Ali; Noroozi-Aghideh, Ali; Shams, Mahmood; Anvar, Ali; Namvar, Ali; Baghaipour, Mohammad Reza; Rad, Fariba; Azadi, Parviz

doi:10.1111/ijlh.13413

Cited by 6 publications

(19 citation statements)

References 10 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to inhibitors in VWD patients, only one study conducted by our team reported one patient (0.3%) with VWD and inhibitors. 12 In addition, it was reported that two patients (<1%) had factor XIII (FXIII) deficiency, 7 13 while five patients (<1%) each were reported to have FVII deficiency and FX deficiency. 12 18 20 21 FV deficiency was reported in two patients (<1%), and congenital fibrinogen disorder and FXI deficiency were reported in one patient each (<1%).…”

Section: Resultsmentioning

confidence: 99%

“…Information about the type of CBDs in hospitalized patients was not provided in five studies, 12 14 15 18 21 and in a study by Perdomo-Amar et al, information about hospitalization was not mentioned. 17 One study utilized a control group to report on the hospitalization rates of COVID-19-infected patients with CBDs.…”

Section: Resultsmentioning

confidence: 99%

“…Of 12 case series studies, mortality information was available in 11 studies (91.6%), 7 8 9 10 11 12 13 14 15 16 17 19 20 21 among which, 5 studies did not observe any death among their patients, 7 8 12 20 21 while others reported deaths among their study population. 13 14 15 16 17 19…”

Section: Resultsmentioning

confidence: 99%

“…7 Our subsequent shortterm prospective study also confirmed this finding. 12 Since then, several studies have been conducted on CBDs in different parts of the world, such as Türkiye, the United States, Europe, Russia, etc., focusing on various aspects of the disease and generating varying results. [13][14][15][16][17] We conducted this systematic literature review to clarify the impact of COVID-19 on patients with CBDs and to evaluate the safety and effectiveness of COVID-19 vaccination in these patients.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Congenital Bleeding Disorders and COVID-19—A Systematic Literature Review

Dorgalaleh,

Safdari,

Tabibian

et al. 2023

Semin Thromb Hemost

Self Cite

View full text Add to dashboard Cite

Hypercoagulability is a prominent feature of coronavirus disease 2019 (COVID-19) and can lead to fatal consequences. Although the impact of COVID-19 on several disorders is well-established, its effect on congenital bleeding disorders (CBDs) is not well-documented. To address this ambiguity, a systematic review was conducted on the available studies to determine the impact of COVID-19 and vaccination aimed to prevent COVID-19 on patients with CBDs. We performed a systematic literature review using relevant keywords and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. We conducted our search on the PubMed, Scopus, and Web of Science databases until July 2023. Out of 31 included studies, 12 case series covering 770 patients with CBD and COVID-19 were further analyzed. The majority of the patients had hemophilia A (n = 352, ∼46%) or hemophilia B (n = 74, ∼10%), while the remaining patients had von Willebrand disease (n = 43, 5.6%) or rare bleeding disorders (n = 27, 3.5%). A total of 25 deaths (3.2%) and 22 intensive care unit admissions (2.8%) were recorded. Bleeding complications were reported in the majority of the 12 case series (n = 7, 58.3%) and in most of the case reports (n = 8, ∼57%), while thrombotic complications were only reported in two studies (16.6%). The mortality rate ranged from 0% in five studies (41.6%) to 5.7% and the rate of hospitalization ranged from 0 to 40%. Bleeding complications were reported in a range of 0 to 81%, while the thrombotic complication rate in one study was 6.9%. The mortality rate varied from 0 to 5.7%, and the hospitalization rate ranged from 0 to 40%. Bleeding complications were reported in a range of 0 to 81%, while the rate of thrombotic complications in one study was 6.9%. Vaccination was reported in five case series, which included 821 patients with CBDs with the majority having hemophilia A (n = 479; 67.2%) and hemophilia B (n = 85; ∼12%). The most frequently reported side effects were myalgia (6.5%), flu-like symptoms (4.8%), fever (4.7%), and headache (4%). COVID-19 in patients with CBDs appears to provoke thrombotic complications and bleeding events more frequently, as well as a higher rate of hospitalization, which may be partially due to the increased risk of bleeding events. Although it seems that patients with CBD have lower mortality rates, further studies are necessary to fully understand this, especially considering comorbidities and low number of available studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Congenital Bleeding Disorders and COVID-19—A Systematic Literature Review

Dorgalaleh,

Safdari,

Tabibian

et al. 2023

Semin Thromb Hemost

Self Cite

View full text Add to dashboard Cite

show abstract

“…Down syndrome (Rank-4) that represents intellectual disability exhibits 4-fold increased risk of severity and 10-fold increased risk of mortality from COVID-19 [193] and autism spectrum disorder (Rank-6) may also be a risk factor [88, 89]. On the other hand, congenital coagulation defects (Rank-4) or congenital bleeding disorders are associated with more favourable outcomes of COVID-19 [194] and fetal hemoglobin (Rank-6) may play a protective role against COVID-19 as the neonates, infants, and children show low prevalence of SARS-CoV-2 infection [195, 196]. Cystic fibrosis (Rank-6) patients may be at risk but are probably not vulnerable to COVID-19 due to their current treatment of cystic fibrosis [197, 198] and according to Paget’s Association, Paget’s disease (Rank-6) is not a risk factor for COVID-19 [199].…”

Section: Resultsmentioning

confidence: 99%

A novel multi-omics-based identification of symptoms, comorbid conditions, and possible long-term complications in COVID-19

Barh

Tiwari

Andrade

et al. 2020

Preprint

View full text Add to dashboard Cite

Till date the comprehensive clinical pictures, comorbid conditions, and long-term complications of COVID-19 are not known. Recently using a multi-omics-based strategy, we have predicted the drugs for COVID-19 management with ∼70% accuracy. Here, using a similar multi-omics-based bioinformatics approach and three-ways of analysis, we identified the symptoms, comorbid conditions, and short, mid and possible long-term complications of COVID-19 with ∼90% precision. In our analysis (i) we identified 27 parent, 170 child, and 403 specific conditions associated with COVID-19. (ii) Among the specific conditions, 36 are viral and 53 short-term, 62 short to mid to long-term, 194 mid to long-term, and 57 are congenital conditions. (iii) At a cut off “count of occurrence” of 4, we found ∼ 90% of the enriched conditions are associated with COVID-19. (iv) Except the dry cough and loss of taste, all other COVID-19 associated mild and severe symptoms are enriched. (v) Cardiovascular, pulmonary, metabolic, musculoskeletal, neuropsychiatric, kidney, liver, and immune system disorders are found as top comorbid conditions. (vi) Specific diseases such as myocardial infarction, hypertension, COPD, lung injury, diabetes, cirrhosis, mood disorders, dementia, macular degeneration, chronic kidney disease, lupus, arthritis etc. along with several other diseases are also enriched as top candidates. (vii) Interestingly, many cancers and congenital disorders associated with COVID-19 severity are also identified. (viii) Arthritis, dermatomyositis, glioma, diabetes, psychiatric disorder, cardiovascular diseases having bidirectional relationship with COVID-19 are also found as top ranked conditions. Based on the accuracy (∼90%) of this analysis, long presence of SARS-CoV-2 RNA in human, and our previously proposed “genetic remittance” assumption, we hypothesize that all the identified comorbid conditions including the short-long-mid and mid-long non-communicable diseases (NCDs) could also be long-term consequences in COVID-19 survivors and warrants long-term observational studies.

show abstract